Yilmaz et al. have demonstrated that rapamycin restored normal HSC function and effectively depleted leukemia-initiating cells simultaneously [67], suggesting that mTOR plays a significant role downstream of the PI3K/PTEN/AKT axis and can be an ideal therapeutic target. The gene discussed is AKT1; the disease is leukemia.